Patent application number | Description | Published |
20130337808 | FACILITATING SERVICE ACCESS FOR MULTI-MODE DEVICES - A method for wireless communication is disclosed. A first attach access point name candidate is selected from an attach access point name list. A long term evolution attach is performed using the selected attach access point name. It is determined whether the long term evolution attach succeeds. A next attach access point name candidate is selected from the attach access point name list if the long term evolution attach using the first attach access point name candidate fails and causes a change of attach access point name. | 12-19-2013 |
20140032987 | REPLACING LOST MEDIA DATA FOR NETWORK STREAMING - In one example, a device includes one or more processors configured to determine that data for at least a portion of a segment of media data has been lost after a remaining portion of the segment has been received via a network transmission in accordance with dynamic adaptive streaming over HTTP (DASH), based on the determination, prior to decoding the media data, add default data to the segment to replace the data that has been determined to be lost to form a replacement segment, and output media data of the replacement segment. | 01-30-2014 |
20140099952 | METHODS AND SYSTEMS FOR AVOIDING TRANSITIONS BETWEEN RADIO ACCESS TECHNOLOGIES WHEN PACKET DATA NETWORKS ARE INACCESSIBLE - Methods and apparatus are provided for avoiding attempts by a UE to attach to a RAT network when that RAT network is unavailable. According to certain aspects, the UE may detect scenarios when the RAT network is unavailable and take preemptive action to prevent the UE from attempting to acquire service on that RAT. For example, the UE may effectively remove that RAT from a list of supported RATs by sending a UE capability message indicating that RAT is not supported, which may prevent network-initiated transitions of the UE to that RAT. The UE may also remove the unavailable RAT from an internal list of supported RATs, which may prevent UE-initiated transitions to that RAT. | 04-10-2014 |
20140126533 | METHOD AND APPARATUS TO REDUCE SIGNALING SPIKES WHEN MOVING BETWEEN WLAN AND WWAN COVERAGE AREAS - Methods and apparatus for wireless communication in a mobile device that includes relinquishing a client side high level operation system (HLOS) internet protocol (IP) context of a user equipment (UE), when the UE, connected to a network via a Wireless Wide Area Network (WWAN) connection, is transported to a Wireless Local Area Network (WLAN) connection area. Aspects of the methods and apparatus include maintaining a Packet Data Protocol (PDP) context of the UE, when the UE, connected to the network via the WWAN connection, is transported to a WLAN connection area. Aspects of the methods and apparatus include setting a linger timer for a certain period of time to defer deactivation of the PDP context and deactivating the PDP context when the linger timer expires. | 05-08-2014 |
20140219157 | MANAGING BROADCAST SERVICES - Methods, systems, and devices are described for managing broadcasts of data in wireless communications. A request to join a multicast session is received. A plurality of broadcast technology based identifiers associated with the multicast session are received. Each broadcast technology based identifier identifies one of a plurality of radio access technologies (RATs) broadcasting the multicast session. One of the plurality of RATs is selected. A multicast stream of data associated with the multicast session is received from the selected RAT. | 08-07-2014 |
Patent application number | Description | Published |
20090117038 | Breast Endothelial Cell Expression Patterns - To gain a better understanding of breast tumor angiogenesis, breast endothelial cells (ECs) were isolated and evaluated for gene expression patterns. When transcripts from breast ECs derived from normal and malignant breast tissues were compared, genes that were specifically elevated in tumor-associated breast endothelium were revealed. These results confirm that neoplastic and normal endothelium in human breast are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future. | 05-07-2009 |
20090136944 | Aberrantly Methylated Genes as Markers of Breast Malignancy - The invention is directed to a method of diagnosing a cell proliferative disorder of breast tissue by determining the methylation status of nucleic acids obtained from a subject. Aberrant methylation of several genes including TWIST, HOXA5, NES-1, retinoic acid receptor beta (RARĪ²), estrogen receptor (ER), cyclin D2, WT-1, 14.3.3 sigma, HIN-1, RASSF1A, and combinations of such genes serve as markers of breast malignancy. | 05-28-2009 |
20100240574 | Heyl as a Therapeutic Target and a Diagnostic Marker for Neoplasia and Uses Therefor - The invention generally features compositions and methods that are useful for treating or diagnosing a neoplasia, in particular breast neoplasia. The invention is based in part on the observation that the basic helix loop helix transcription factor HEYL was found to be overexpressed in breast cancer cells. Accordingly, the invention provides therapeutic compositions and methods for altering the levels and expression of HEYL of the invention, thereby treating a neoplasia, as well as compositions and methods for diagnosing a neoplasia. | 09-23-2010 |
20100285031 | Hox Compositions and Methods - The present invention relates to compositions to treat HOXB7 related disorders. The invention also relates to methods treating HOXB7 related disorders. The invention further relates to kits for treating HOXB7 related disorders in a subject. The invention further relates to methods of identifying novel treatments for treating HOXB7 related disorders in a subject. | 11-11-2010 |
20110262350 | BREAST ENDOTHELIAL CELL EXPRESSION PATTERNS - To gain a better understanding of breast tumor angiogenesis, breast endothelial cells (ECs) were isolated and evaluated for gene expression patterns. When transcripts from breast ECs derived from normal and malignant breast tissues were compared, genes that were specifically elevated in tumor-associated breast endothelium were revealed. These results confirm that neoplastic and normal endothelium in human breast are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future. | 10-27-2011 |
20130333059 | HOX COMPOSITIONS AND METHODS - The present invention relates to compositions to treat HOXB7 related disorders. The invention also relates to methods treating HOXB7 related disorders. The invention further relates to kits for treating HOXB7 related disorders in a subject. The invention further relates to methods of identifying novel treatments for treating HOXB7 related disorders in a subject. | 12-12-2013 |
20140056911 | Breast Endothelial Cell Expression Patterns - To gain a better understanding of breast tumor angiogenesis, breast endothelial cells (ECs) were isolated and evaluated for gene expression patterns. When transcripts from breast ECs derived from normal and malignant breast tissues were compared, genes that were specifically elevated in tumor-associated breast endothelium were revealed. These results confirm that neoplastic and normal endothelium in human breast are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future. | 02-27-2014 |
20140171483 | COMPOSITIONS AND METHODS FOR TREATMENT OF TAMOXIFEN RESISTANT BREAST CANCER - The inventors found that the gene, HOXB7, was frequently overexpressed in breast cancer, and is a major upstream regulator of events leading to tamoxifen resistance. The present invention provides double-stranded short interfering nucleic acid (siNA) molecules that targets the HOXB7 gene in cells, and also provides methods of use of this siNA molecule for methods of screening, diagnosis and prediction of treatment outcomes as well as treatment of cancer. | 06-19-2014 |
20140220561 | QUANTITATIVE MULTIPLEX METHYLATION-SPECIFIC PCR - Methods are provided for diagnosing in a subject a condition, such as a carcinoma, sarcoma or leukemia, associated with hypermethylation of genes by isolating the genes from tissue containing as few as 50 to 1000 tumor cells. Using quantitative multiplex methylation specific PCR (QM-MSP), multiple genes can be quantitatively evaluated from samples usually yielding sufficient DNA for analyses of only 1 or 2 genes. DNA sequences isolated from the sample are simultaneously co-amplified in an initial multiplex round of PCR, and the methylation status of individual hypermethylation-prone gene promoter sequences is then determined separately or in multiplex using a real time PCR round that is methylation status-specific. Within genes of the panel, the level of promoter hypermethylation as well as the incidence of promoter hypermethylation can be determined and the level of genes in the panel can be scored cumulatively. The QM-MSP method is adaptable for high throughput automated technology. | 08-07-2014 |
20150057188 | Quantitative Multiplex Methylation-Specific PCR - Methods are provided for diagnosing in a subject a condition, such as a carcinoma, sarcoma or leukemia, associated with hypermethylation of genes by isolating the genes from tissue containing as few as 50 to 1000 tumor cells. Using quantitative multiplex methylation specific PCR (QM-MSP), multiple genes can be quantitatively evaluated from samples usually yielding sufficient DNA for analyses of only 1 or 2 genes. DNA sequences isolated from the sample are simultaneously co-amplified in an initial multiplex round of PCR, and the methylation status of individual hypermethylation-prone gene promoter sequences is then determined separately or in multiplex using a real time PCR round that is methylation status-specific. Within genes of the panel, the level of promoter hypermethylation as well as the incidence of promoter hypermethylation can be determined and the level of genes in the panel can be scored cumulatively. The QM-MSP method is adaptable for high throughput automated technology. | 02-26-2015 |
20150094222 | QUANTITATIVE MULTIPLEX METHYLATION SPECIFIC PCR METHOD- cMethDNA, REAGENTS, AND ITS USE - The cMethDNA method of the present invention is a novel modification of the QM-MSP method (U.S. Pat. No. 8,062,849), specifically intended to quantitatively detect tumor DNA (or other circulating DNAs) in fluids such as serum or plasma at the lowest copy number yet reported. Unique compared to any other PCR-based assay, a small number of copies of a synthetic polynucleotide standard (STDgene) is added to an aliquot of patient serum. In a standard procedure, a cocktail of standards for a plurality of genes of interest (TARGETgene) is added to a sample of serum. Once total DNA is purified and processed, a PCR (multiplex step) is performed wherein the STDgene and the TARGETgene are co-amplified with the same external primer set. In the N second nested PCR step, amplicons present in a dilution of the first PCR reaction are subjected to real time PCR, and quantified for each gene in one well by two-color real-time PCR. Products are calculated by absolute quantitation with internal primer sets specific for the methylated TARGETgene and associated STDgene. Methods of making the STDgene standards and the use of the cMethDNA methods and kits containing the same are disclosed. | 04-02-2015 |
Patent application number | Description | Published |
20090155278 | Claudins as Markers for Early Detection, Diagnosis, Prognosis and as Targets of Therapy for Breast and Metastatic Brain or Bone Cancer - Methods of diagnosis, prognosis, and treatment of breast cancer, and of metastatic brain cancer, are provided The diagnostic and prognostic methods involve the immunohistochemical detection of the level of expression of the proteins claudin 1, 3, 4, and 7 in tissue or cell samples. Claudins 1 and 7 are underexpressed in the majority of breast cancers, and claudins 3 and 4 are overexpressed. The methods of treatment involve the use of | 06-18-2009 |
20140221242 | GENOME-WIDE METHYLATION ANALYSIS AND USE TO IDENTIFY GENES SPECIFIC TO BREAST CANCER HORMONE RECEPTOR STATUS AND RISK OF RECURRANCE - To better understand the biology of hormone receptor-positive and negative breast cancer and to identify methylated gene markers of disease progression, a genome-wide methylation array analysis was performed on 103 primary invasive breast cancers and 21 normal breast samples using the Illumina Infinium HumanMethylation27 array that queried 27,578 CpG loci. Forty CpG loci showed differential methylation specific to either ER-positive or ER-negative tumors. Each of the 40 ER-subtype-specific loci was validated in silico using an independent, publicly available methylome dataset from The Cancer Genome Atlas (TCGA). In addition, 100 methylated CpG loci were identified that were significantly associated with disease progression. Arrays containing the ER-subtype-specific loci and their use in methods of diagnosis and treatment of breast cancer are provided. | 08-07-2014 |
Patent application number | Description | Published |
20100184148 | IN VITRO GERMINAL CENTERS - The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days. | 07-22-2010 |
20110250620 | METHODS OF EVALUATING AN IMMUNE RESPONSE TO AN ANTIGEN - The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days. | 10-13-2011 |
20110269176 | METHODS FOR ASSAYING RESPONSES TO VACCINES - The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days. | 11-03-2011 |
Patent application number | Description | Published |
20140274914 | ACH-0142684 SODIUM SALT POLYMORPH, COMPOSITION INCLUDING THE SAME, AND METHOD OF MANUFACTURE THEREOF - The disclosure provides a crystalline sodium salt of ACH-0142684 comprising a Form A polymorph, a Form B polymorph, a Form C polymorph, a Form D polymorph, a Form E polymorph, a Form F polymorph, a Form G polymorph, a Form H polymorph, a Form I polymorph, or a combination thereof, wherein the Form A, B, C, D, E, F, G, H, and I polymorph exhibits an X-ray powder diffraction pattern having peak locations in accordance with FIGS. | 09-18-2014 |
Patent application number | Description | Published |
20120078995 | SYSTEM AND METHOD FOR WARMING AN OPTIMIZATION DEVICE - A system and method are provided for warming a network intermediary (e.g., a proxy, a transaction accelerator) to enable it to provide effective optimization (e.g., data reduction) without a cold start. When a pair of network intermediaries cooperate to optimize a communication connection (e.g., between a client and a server), either or both intermediaries may form branch channels with one or more peers. Via these branch channels, the intermediaries may forward optimization information such as data references received from the other intermediary (i.e., in place of data segments, as part of a data reduction scheme), and/or resolve unknown references. | 03-29-2012 |
20120096237 | METHOD OF IMPROVING PERFORMANCE OF A DATA STORAGE DEVICE - Methods are provided for efficiently storing data to a data storage device or subsystem. The data storage device may be a Solid-State Device (SSD), and may be implemented as part of a RAID (Redundant Array of Independent Disks) or other subsystem. When existing data is read and updated, and must be re-stored, the data is assembled and stored as if it were new data, and is written in a sequential manner, instead of being written to the same storage location. A newer generation number distinguishes it from the previous version. If the storage subsystem employs data striping, stripe size may be matched with the size of a logical collection of data (e.g., an extent), so that each such logical collection of data is wholly stored on just device in the storage subsystem. Concurrent device access may be supported by concurrently writing substripes of data to each device/extent. | 04-19-2012 |